United States Patent 11,724,036: What Claims Cover, Who Owns It, and What Patent Landscape Does It Block
US Patent 11,724,036 defines enforceable protection around a specific claimed invention and is part of a wider US patent estate that can constrain generic or biosimilar-style entry if a challenger practices the claimed subject matter. The scope of the impact turns on (i) the independent claim architecture, (ii) whether dependent claims narrow to specific embodiments, (iii) the priority chain that anchors claim support, and (iv) whether related continuation or improvement filings expand coverage in the US.
No analysis can be produced because the underlying patent record for US 11,724,036 (claims, specification, assignees, priority/filing dates, family members, and legal status) is not present in the prompt, and producing an “answer” without those inputs would require inventing facts.
What is claimed in US Patent 11,724,036 and how broad are the independent claims?
The patent file contents are required to extract claim language, identify claim dependencies, and map claim elements to potential infringement pathways. Without the actual claims text and claim chartable elements, claim breadth cannot be analyzed.
Which dependent claims likely add narrowing limitations
Dependent claim parsing requires claim-by-claim text, including introductory phrases, element recitations, and any “wherein” limitations. No such claim text is included.
Do the claims target a product, method, or use
Claim category cannot be determined without the independent claim(s) and their preambles.
Who owns US Patent 11,724,036 and what assignee or inventors define the estate?
Ownership and inventor identity require the USPTO assignment and bibliographic data. No bibliographic or assignment data is included.
Is the patent held by a brand company, platform owner, or licensee
This is determined by assignee history and any intervening assignment documents, which are not provided.
What is the priority chain for US 11,724,036 and when does it expire?
Expiration requires priority dates, term adjustments, and any terminal disclaimers. Without filing/priority dates, USPTO term calculations are not possible.
Does it have PTA/PTE or terminal disclaimers that change expiry
PTA/PTE and disclaimers are legal-document details that must come from the patent record.
What filing dates drive the term under 35 USC 154
Term under 35 USC 154 depends on earliest non-provisional filing date. That date is not given.
Which other family members exist that expand protection beyond US 11,724,036?
A family landscape requires priority family mapping across US publications, continuations, divisionals, and foreign counterparts. No publication numbers or family members are provided.
Are there continuation or continuation-in-part (CIP) claims that broaden coverage
This requires prosecution history and related US publication listings, absent from the prompt.
Do foreign filings indicate similar claim scope or different carve-outs
Foreign claim sets can diverge materially and must be reviewed using the actual country family data.
How strong is the enforceability of US Patent 11,724,036 in US courts?
Enforceability analysis requires: claim construction posture, whether the patent survived office actions, and any PTAB outcomes (IPR/PGR), plus litigation history.
Has the patent been challenged in IPR or PGR
PTAB docket data is not provided.
What litigation history exists for US 11,724,036
No suit identifiers or court dockets are included.
What patent claims create the biggest barriers to generic entry or design-around?
This requires mapping claimed elements to feasible design-arounds and generic/competitor product configurations, based on the exact claims.
What design-around pathways are likely blocked by claim “wherein” limitations
This depends on the dependent claim limitations and structural/method element recitations.
Does the claim require specific materials, parameters, or process steps
Only the claim text identifies required parameters and process conditions.
How does US Patent 11,724,036 compare with related patents in the same therapeutic or technical space?
Comparison requires the surrounding patent landscape: nearest prior patents, family members, competitors’ patents, and any overlapping claim categories. None are provided.
Which claims overlap with competitor estates
A comparison demands claim charts or at least element-by-element review across cited patents and competitor filings.
What does the regulatory pathway status imply for infringement risk tied to US 11,724,036?
This requires the drug or product context (NDA/BLA/ANDA), Orange Book listing status, and any paragraph IV certifications referencing the patent. The prompt does not include the relevant product identity.
Is the patent listed in the Orange Book and for what drug(s)
Orange Book listings cannot be derived without knowing the covered active ingredient/product.
Do any ANDAs reference US 11,724,036 via paragraph IV
That data is absent.
Key Takeaways
- US Patent 11,724,036’s claim scope, ownership, family landscape, enforceability posture, and market blocking effect cannot be determined from the prompt because the necessary patent record content is not included.
- A complete critical analysis requires the actual claims and bibliographic/legal data from the patent file and its family.
FAQs
- What claim elements would most likely be targeted in an infringement allegation for US 11,724,036?
- Does US 11,724,036 have continuation claims that extend protection beyond the original filing?
- Has US 11,724,036 been subject to PTAB review, and what were the outcomes?
- If US 11,724,036 is Orange Book-listed, which ANDA paragraph IV certifications reference it?
- What is the earliest possible expiry date for US 11,724,036 under 35 USC 154 given its priority and any PTA/PTE?
References
- United States Patent and Trademark Office. US Patent 11,724,036. (Patent record not provided in prompt.)
